InSync Model 8040 (InSync) and InSync III Model 8042 (InSync III) Registry

NCT ID: NCT00273182

Last Updated: 2013-08-05

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1999 participants

Study Classification

OBSERVATIONAL

Study Start Date

2002-03-31

Study Completion Date

2011-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Heart failure is a progressive disease that decreases the pumping action of the heart. This may cause a backup of fluid in the heart and may result in heart beat changes.

When there are changes in the heart beat sometimes an implantable heart device is used to control the rate and rhythm of the heart beat. In certain heart failure cases, when the two lower chambers of the heart no longer beat in a coordinated manner, cardiac resynchronization therapy (CRT) may be prescribed. CRT is similar to a pacemaker. It is placed (implanted) under the skin of the upper chest. CRT is delivered as tiny electrical pulses to the right and left ventricles through three or four leads (soft insulated wires) that are inserted through the veins to the heart.

The purpose of this study is to monitor the long-term performance of the InSync Model 8040 (InSync) and InSync III Model 8042 (InSync III) systems for cardiac resynchronization therapy (CRT).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Condition of Approval study for cardiac resynchronization therapy with pacemakers, and for the Attain left ventricular leads 2187, 2188, 4193, and 4194.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Cardiomyopathy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Heart Failure Cardiomyopathy Cardiac pacing Cardiac resynchronization therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort

Patients implanted with InSync Model 8040, InSync III Model 8042 , or Medtronic CRT-D system. A total of 1999 subjects were enrolled in the study. Of them, 1738 had successful post market implants of InSync Model 8040 (601 subjects), InSync III Model 8042 (512 subjects) and CRT-D devices (625 subjects). The rest 262 subjects came from two pre-market studies: the MIRACLE study added 141 subjects to InSync Model 8040, and the InSync III study added 121 subjects to the InSync III Model 8042. A total of 1014 subjects completed the study through 36 month follow up. Follow-up of 1000 subjects was required by the FDA to satisfy the conditions of approval.

InSync Model 8040

Intervention Type DEVICE

Subjects with sucessful implants of InSync Model 8040.

InSync III Model 8042

Intervention Type DEVICE

Subjects with successful implants of InSync III Model 8042

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

InSync Model 8040

Subjects with sucessful implants of InSync Model 8040.

Intervention Type DEVICE

InSync III Model 8042

Subjects with successful implants of InSync III Model 8042

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients implanted with an InSync Model 8040 or InSync III Model 8042, a right ventricular lead, and a Medtronic market-released left ventricular lead as part of a system to deliver cardiac resynchronization therapy.

Exclusion Criteria

* Patients with a history of a previously failed placement of a currently investigational Medtronic left ventricular lead within 30 days of enrollment in the InSync Registry
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic Cardiac Rhythm and Heart Failure

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

InSync Registry Study Leader

Role: STUDY_CHAIR

Medtronic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Birmingham, Alabama, United States

Site Status

Peoria, Arizona, United States

Site Status

Fort Smith, Arkansas, United States

Site Status

Little Rock, Arkansas, United States

Site Status

Long Beach, California, United States

Site Status

Napa, California, United States

Site Status

Oxnard, California, United States

Site Status

San Diego, California, United States

Site Status

Yuba City, California, United States

Site Status

Washington D.C., District of Columbia, United States

Site Status

Gainesville, Florida, United States

Site Status

Jacksonville, Florida, United States

Site Status

Jupiter, Florida, United States

Site Status

Melbourne, Florida, United States

Site Status

Miami, Florida, United States

Site Status

Orlando, Florida, United States

Site Status

Tampa, Florida, United States

Site Status

Atlanta, Georgia, United States

Site Status

Rockford, Illinois, United States

Site Status

Springfield, Illinois, United States

Site Status

Indianapolis, Indiana, United States

Site Status

Des Moines, Iowa, United States

Site Status

Kansas City, Kansas, United States

Site Status

Overland Park, Kansas, United States

Site Status

Lexington, Kentucky, United States

Site Status

Louisville, Kentucky, United States

Site Status

Lake Charles, Louisiana, United States

Site Status

Shreveport, Louisiana, United States

Site Status

Baltimore, Maryland, United States

Site Status

Salisbury, Maryland, United States

Site Status

Silver Spring, Maryland, United States

Site Status

Boston, Massachusetts, United States

Site Status

Worchester, Massachusetts, United States

Site Status

Detroit, Michigan, United States

Site Status

Kalamazoo, Michigan, United States

Site Status

Lansing, Michigan, United States

Site Status

Marquette, Michigan, United States

Site Status

Saginaw, Michigan, United States

Site Status

Duluth, Minnesota, United States

Site Status

Minneapolis, Minnesota, United States

Site Status

Hattiesburg, Mississippi, United States

Site Status

Tupelo, Mississippi, United States

Site Status

Columbia, Missouri, United States

Site Status

Kansas City, Missouri, United States

Site Status

Saint Joseph, Missouri, United States

Site Status

Springfield, Missouri, United States

Site Status

St Louis, Missouri, United States

Site Status

Billings, Montana, United States

Site Status

Lincoln, Nebraska, United States

Site Status

Newark, New Jersey, United States

Site Status

Manhasset, New York, United States

Site Status

New York, New York, United States

Site Status

Rochester, New York, United States

Site Status

Chapel Hill, North Carolina, United States

Site Status

Charlotte, North Carolina, United States

Site Status

High Pointe, North Carolina, United States

Site Status

Raleigh, North Carolina, United States

Site Status

Winston-Salem, North Carolina, United States

Site Status

Cincinnati, Ohio, United States

Site Status

Cleveland, Ohio, United States

Site Status

Columbus, Ohio, United States

Site Status

Mayfield Heights, Ohio, United States

Site Status

Oklahoma City, Oklahoma, United States

Site Status

Doylestown, Pennsylvania, United States

Site Status

Erie, Pennsylvania, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

York, Pennsylvania, United States

Site Status

Providence, Rhode Island, United States

Site Status

Greenville, South Carolina, United States

Site Status

Spartanburg, South Carolina, United States

Site Status

Nashville, Tennessee, United States

Site Status

Dallas, Texas, United States

Site Status

Fort Worth, Texas, United States

Site Status

Houston, Texas, United States

Site Status

Lubbock, Texas, United States

Site Status

Sherman, Texas, United States

Site Status

Salt Lake City, Utah, United States

Site Status

Richmond, Virginia, United States

Site Status

Virginia Beach, Virginia, United States

Site Status

Seattle, Washington, United States

Site Status

Morgantown, West Virginia, United States

Site Status

Milwaukee, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Johnson WB, Abraham WT, Young JB, Wheelan K, Smith AL, Chang Y, Brinkman P; InSync Registry Investigators. Long-term performance of the attain model 4193 left ventricular lead. Pacing Clin Electrophysiol. 2009 Sep;32(9):1111-6. doi: 10.1111/j.1540-8159.2009.02451.x.

Reference Type DERIVED
PMID: 19719485 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

187

Identifier Type: -

Identifier Source: org_study_id